Top Upgrades

  • Goldman Sachs upgraded Myriad Genetics, Inc. (NASDAQ:MYGN) from Sell to Neutral. Myriad Genetics shares rose 2.1 percent to $32.72 in pre-market trading.
  • Citi upgraded Sony Corp (NYSE:SNE) from Neutral to Buy. Sony rose 2 percent to $52.91 in pre-market trading.
  • Citigroup upgraded Nantkwest Inc (NASDAQ:NK) from Sell to Neutral. NantKwest shares fell 4.02 percent to close at $1.67 on Thursday.
  • Analysts at Goldman Sachs upgraded Abbott Laboratories (NYSE:ABT) from Neutral to Buy. Abbott shares rose 1.2 percent to $74.10 in pre-market trading.
  • Barclays upgraded Fair Isaac Corporation (NYSE:FICO) from Equal-Weight to Overweight. Fair Isaac shares rose 2.26 percent to close at $190.44 on Thursday.
  • Loop Capital upgraded Coupa Software Inc (NASDAQ:COUP) from Hold to Buy. Coupa Software shares rose 3.7 percent to $65.00 in pre-market trading.
  • JP Morgan upgraded World Wrestling Entertainment, Inc. (NYSE:WWE) from Neutral to Overweight. WWE shares rose 4.1 percent to $75.00 in pre-market trading.
  • First Analysis upgraded Palo Alto Networks Inc (NYSE:PANW) from Outperform to Strong Buy. Palo Alto shares rose 0.5 percent to $177.00 in pre-market trading.
  • JP Morgan upgraded Cubic Corporation (NYSE:CUB) from Neutral to Overweight. Cubic shares fell 3.23 percent to close at $59.03 on Thursday.
  • Wells Fargo upgraded Under Armour Inc (NYSE:UAA) from Underperform to Market Perform. Under Armour shares rose 1.6 percent to $23.50 in pre-market trading.

 

Top Downgrades

  • Goldman Sachs downgraded Quest Diagnostics Inc (NYSE:DGX) from Buy to Neutral. Quest shares rose 0.4 percent to $88.25 in pre-market trading.
  • Bank of America downgraded Goldman Sachs Group Inc (NYSE:GS) from Buy to Neutral. Goldman Sachs shares fell 2 percent to $190.98 in pre-market trading.
  • JP Morgan downgraded Cree, Inc. (NASDAQ:CREE) from Neutral to Underweight. Cree shares fell 0.28 percent to close at $45.96 on Thursday.
  • Mizuho downgraded Assertio Therapeutics Inc (NASDAQ:ASRT) from Buy to Neutral. Assertio Therapeutics shares fell 1.33 percent to close at $5.21 on Thursday.
  • UBS downgraded Hannon Armstrong Sustnbl Infrstr Cap Inc (NYSE:HASI) from Buy to Neutral. Hannon Armstrong shares fell 3.2 percent to $23.00 in pre-market trading.
  • Goldman Sachs downgraded Waters Corporation (NYSE:WAT) from Neutral to Sell. Waters shares fell 1.3 percent to $200.83 in pre-market trading.
  • Citigroup downgraded Sodexo SA (OTC:SDXAY) from Buy to Neutral. Sodexo shares fell 1.14 percent to close at $20.76 on Thursday.
  • Bank of America downgraded Sprouts Farmers Market Inc (NASDAQ:SFM) from Buy to Underperform. Sprouts Farmers shares fell 11.3 percent to $23.98 in pre-market trading.
  • Longbow Research downgraded American Woodmark Corporation (NASDAQ:AMWD) from Buy to Neutral. American Woodmark shares fell 1.55 percent to close at $66.85 on Wednesday.
  • DNB Markets downgraded Frontline Ltd (NYSE:FRO) from Buy to Hold. Frontline shares fell 10.1 percent to $7.30 in pre-market trading.

 

Top Initiations

  • Needham initiated coverage on Crispr Therapeutics AG (NASDAQ:CRSP) with a Buy rating. The price target for Crispr Therapeutics is set to $62. Crispr Therapeutics shares closed at $38.72 on Thursday.
  • Analysts at Raymond James initiated coverage on Everi Holdings Inc (NYSE:EVRI) with a Strong Buy rating. The price target for Everi is set to $11. Everi shares closed at $6.52 on Thursday.
  • H.C. Wainwright initiated coverage on Forty Seven Inc (NASDAQ:FTSV) with a Buy rating. The price target for Forty Seven is set to $21. Forty Seven shares closed at $17.66 on Thursday.
  • Analysts at Needham initiated coverage on Casa Systems Inc (NASDAQ:CASA) with a Buy rating. The price target for Casa Systems is set to $19. Casa Systems closed at $15.08 on Thursday.
  • Analysts at Jefferies initiated coverage on Eastgroup Properties Inc (NYSE:EGP) with a Hold rating. The price target for Eastgroup Properties is set to $99. Eastgroup Properties shares closed at $100.23 on Thursday.
Market News and Data brought to you by Benzinga APIs

Comments
Loading...